Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma
2021 · Scientific Reports · 54 citations
https://doi.org/10.1038/s41598-021-84733-5
N
Nobuyo Higashi‐Kuwata
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
42
Papers
981
Citations
13
h-index
17
i10-index
Nobuyo Higashi‐Kuwata is an academic researcher from National Center for Global Health and Medicine. The author has contributed to research in topics: SARS-CoV-2 and COVID-19 Research & HIV/AIDS drug development and treatment & Hepatitis B Virus Studies. The author has an h-index of 13, co-authored 36 publications.
ORCID: 0000-0002-9404-3532Papers by this author
worksIdentification of SARS-CoV-2 Mpro inhibitors containing P1’ 4-fluorobenzothiazole moiety highly active against SARS-CoV-2
2023 · Nature Communications · 44 citations
https://doi.org/10.1038/s41467-023-36729-0
Identification of a novel long-acting 4’-modified nucleoside reverse transcriptase inhibitor against HBV
2020 · Journal of Hepatology · 28 citations
https://doi.org/10.1016/j.jhep.2020.12.006
Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron
2023 · Scientific Reports · 12 citations
https://doi.org/10.1038/s41598-023-44484-x
A novel anti-HBV agent, E-CFCP, restores Hepatitis B virus (HBV)-induced senescence-associated cellular marker perturbation in human hepatocytes
2023 · Virus Research · 8 citations
https://doi.org/10.1016/j.virusres.2023.199094
Tecovirimat is active against various MPXV strains, while cidofovir, brincidofovir, trifluridine, and gemcitabine have no detectable MPXV-specific antiviral activity
2025 · Virus Research · 2 citations
https://doi.org/10.1016/j.virusres.2025.199615
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat